Gilead Strengthens Inflammation Portfolio With Ouro Medicines Deal [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
The deal brings a clinical-stage bispecific T-cell engager, OM336 (gamgertamig), into Gilead's inflammation portfolio, adding a potentially first-in-class approach aimed at delivering durable immune reset. Gilead will acquire Ouro for $1.675 billion upfront, with up to $500 million in additional milestone payments. The transaction remains subject to regulatory approvals and customary closing conditions. Gilead Sciences, Inc. Price, Consensus and EPS Surprise Gilead Sciences, Inc. price-consensus-eps-surprise-chart | Gilead Sciences, Inc. Quote More on GILD's Announced Ouro Acquisition The acquisition reflects Gilead's strategy to expand into next-generation immunology treatments, particularly T-cell engager platforms that may offer long-lasting disease control or even drug-free remission by resetting the immune system. This modality complements Gilead's broader portfolio of CAR-T assets. OM336 is currently being studied under an active investigational new drug (IND) appli
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic? [Yahoo! Finance]Yahoo! Finance
- Gilead: Why The 'Immune System Company' Pivot Is No Longer A Bargain (Downgrade) [Seeking Alpha]Seeking Alpha
- Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline [Yahoo! Finance]Yahoo! Finance
- Gilead Eyes $2.2 Billion Autoimmune Push With Ouro Deal [Yahoo! Finance]Yahoo! Finance
- Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 3/27/26 - Form 144
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form ARS
- GILD's page on the SEC website